Targeted Clinical Research to Address Select Viral Infections-A Phase II Randomized Six Weeks of Oral Valganciclovir Therapy in CMV Infants with Hearing Loss

Grant

Total Award Amount

  • 4492114.00
  • Direct Costs

  • 3549429.00
  • Sponsor Award Id

  • HHSN272201100035C
  • Contributor

  • David Kimberlin M.D.   Investigator  
  • Gary Cutter   Investigator  
  • Richard Whitley M.D.   Principal Investigator